Asabys, Alta Life lead funding round for Inbrain

Finaves, the venture capital arm of the IESE Business School, also took part in the investment, alongside the Institut Català de Finances (ICF), the Instituto Catalán de Nanociencia y Nanotecnología (ICN2) and the Catalan Institution for Research and Advanced Studies, a foundation launched by the Catalan regional government to support scientific research.

The investors in the round plan to attract additional backers and reach total funding of around €15m. Inbrain intends to use the fresh capital to further develop its graphene-based implant and interface technology.

Healthcare-focused venture capital firm Asabys is backed by Spanish bank Banc Sabadell as anchor investor, while Alantra controls a minority stake in the firm. Asabys manages Sabadell Asabys Health Innovation Investments, which was launched in 2019 with an €80m target and has raised €60m so far.

Alta Life is investing from its debut fund, Alta Life Sciences Spain 1, which targets companies operating in the biotech, diagnostics and digital health sectors.

Company
Founded in 2019 and based in Barcelona, Inbrain develops graphene brain implants to treat neurodegenerative diseases.

Its brain interface has the capability of detecting therapy-specific biomarkers and triggering highly focal adaptive neuromodulation for increased outcomes in personalised neurological therapies.

People
Asabys Partners – Josep Lluís Sanfeliu (founding partner).
Alta Life Sciences – Montserrat Vendrell (partner).
Inbrain – José Garrido, Carolina Aguilar (co-founders).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Technology
• Venture
• Spain